Data on aspirin use to reduce cancer risk come
largely from observational studies, with relatively few
data from randomized controlled trials. Furthermore,
cardiovascular disease prevention has been the primary
endpoint in most trials, limiting knowledge about
the best timing and dose for cancer risk reduction